Ta' Braxia Cemetery

Update on LOI for Business Combination with Braxia Scientific Corp.

Retrieved on:

Thursday, March 16, 2023

Ta' Braxia Cemetery, FRA, OTC, News, Growth, Letter, CSE, Management

LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), announced today that it has terminated the non-binding amended and restated letter of intent ("LOI") for a business combination with Braxia Scientific Corp. ("Braxia"), (the "Proposed Transaction").

Key Points:

LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), announced today that it has terminated the non-binding amended and restated letter of intent ("LOI") for a business combination with Braxia Scientific Corp. ("Braxia"), (the "Proposed Transaction").
The Company's news release dated January 27, 2023, contained full details of the Proposed Transaction.
Despite this, he expressed his admiration for the Braxia management team and wished them well in their future endeavors.
Irwin Naturals remains committed to driving growth and value for its stakeholders and is confident in its ability to achieve its strategic objectives.

REPEAT - Irwin Naturals Closes Acquisition of Leading Kentucky Clinic adding $3 Million in Projected EBITDA, Company delivering on ambitious strategy to build largest global network of mental health clinics

Retrieved on:

Tuesday, February 21, 2023

Serenity, OTC, Acquisition, FRA, EBITDA, Patient, Ta' Braxia Cemetery, CSE, Psychiatry, Pharmaceutical industry

The acquisition, completed on February 16, 2023, marks two key milestones in Irwin’s Emergence clinics growth strategy in the mental health industry.

Key Points:

The acquisition, completed on February 16, 2023, marks two key milestones in Irwin’s Emergence clinics growth strategy in the mental health industry.
Klee Irwin, the CEO of Irwin Naturals, "With each clinic we bring under the Irwin Naturals Emergence umbrella, we establish our leadership in this innovative approach to mental healthcare.
The acquisition of Serenity Health by Irwin Naturals Emergence is a strategic move aimed at providing accessible and affordable mental healthcare to patients.
Braxia (“Braxia Scientific”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders (“Braxia LOI”).

Irwin Naturals Closes Acquisition of Leading Kentucky Clinic adding $3 Million in Projected EBITDA, Company delivering on ambitious strategy to build largest global network of mental health clinics

Retrieved on:

Saturday, February 18, 2023

Serenity, OTC, Acquisition, FRA, EBITDA, Patient, Ta' Braxia Cemetery, CSE, Psychiatry, Pharmaceutical industry

The acquisition, completed on February 16, 2023, marks two key milestones in Irwin’s Emergence clinics growth strategy in the mental health industry.

Key Points:

The acquisition, completed on February 16, 2023, marks two key milestones in Irwin’s Emergence clinics growth strategy in the mental health industry.
Klee Irwin, the CEO of Irwin Naturals, "With each clinic we bring under the Irwin Naturals Emergence umbrella, we establish our leadership in this innovative approach to mental healthcare.
The acquisition of Serenity Health by Irwin Naturals Emergence is a strategic move aimed at providing accessible and affordable mental healthcare to patients.
Braxia (“Braxia Scientific”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders (“Braxia LOI”).

Glancy Prongay & Murray LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Champignon Brands Inc. n/k/a Braxia Scientific Corp. shares - BRAXF

Retrieved on:

Wednesday, December 14, 2022

SANTA ANA, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP announces that the United States District Court for the Central District of California has approved the following announcement of a proposed securities class action settlement that would benefit purchasers of Braxia shares on the OTC stock market (OTCMKTS: BRAXF).

Key Points:

SANTA ANA, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP announces that the United States District Court for the Central District of California has approved the following announcement of a proposed securities class action settlement that would benefit purchasers of Braxia shares on the OTC stock market (OTCMKTS: BRAXF).
YOU ARE ALSO NOTIFIED that Lead Plaintiff in the Action has reached a proposed settlement of the Action for $1,000,000 in cash (the “Settlement”), that, if approved, will resolve all claims in the Action.
If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund.
All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Lead Counsel or the Claims Administrator.

Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients

Retrieved on:

Monday, August 29, 2022

Braxia Scientific completed the acquisition and launch of KetaMD, a new end-to-end telemedicine platform, that utilizes leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions.

Key Points:

Braxia Scientific completed the acquisition and launch of KetaMD, a new end-to-end telemedicine platform, that utilizes leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions.
Treatments are medically supervised, guided virtually by registered nurses with mental health expertise, and backed by the world's leading psychiatrists and researchers in depression.
KetaMD is currently available in theState of Floridawith a roll-out to other key states to begin in 2022.
Braxia Health received multiple approvals from Health Canada to the Special Access Program ("SAP") to provide psilocybin-assisted psychotherapy for patients with Major Depressive Disorder outside of clinical trials.

Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth

Retrieved on:

Wednesday, July 27, 2022

These strategic hires bolster Braxia's senior leadership team and its ability to drive growth and innovation.

Key Points:

These strategic hires bolster Braxia's senior leadership team and its ability to drive growth and innovation.
Jason also brings deep expertise in both revenue cycle, data management and mining, and a proven ability to manage product development.
Jason is also a founding board member for a rare disease foundation working towards building treatments for children with Neurodegenerative disorders.
Dr. McIntyre commented, "We are delighted to welcome Daniel, adding high caliber global pharmaceutical leadership to the Braxia management team.

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

Retrieved on:

Friday, June 24, 2022

Braxia Scientific CEO Dr. Roger McIntyre will deliver two live presentations at the conference beginning with a Keynote address - Introduction to the State of Mental Healthcare to kick off the conference on Monday, June 27 at 8:15 a.m.

Key Points:

Braxia Scientific CEO Dr. Roger McIntyre will deliver two live presentations at the conference beginning with a Keynote address - Introduction to the State of Mental Healthcare to kick off the conference on Monday, June 27 at 8:15 a.m.
ET
Dr. McIntyre, will also deliver a second presentation on Monday, June 27 at 4:00 p.m.
Braxia's trials include Canada's first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and recently reported positive preliminary results.
Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others.

Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Depression and Related Mental Health Disorders

Retrieved on:

Wednesday, June 15, 2022

The Kitchen-waterloo location is the fifth Braxia Health Clinic in Canada.

Key Points:

The Kitchen-waterloo location is the fifth Braxia Health Clinic in Canada.
"Further plans are in place for the expansion of Braxia Health clinics in Toronto and Ottawa, Ont., to better serve the growing unmet need in our Canadian communities.
Additionally, Braxia Health clinics have begun to expand current offerings across its centers to include IV and oral ketamine.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

Retrieved on:

Thursday, June 2, 2022

(1) Symptoms of depression were assessed using the Montgomery-sberg depression rating scale (MADRS), a widely used and accepted scale for assessing depression.

Key Points:

(1) Symptoms of depression were assessed using the Montgomery-sberg depression rating scale (MADRS), a widely used and accepted scale for assessing depression.
Braxia Scientific is a leader in providing access to innovative rapid acting treatments such as ketamine and psilocybin for people living with treatment resistant depression.
This ongoing clinical trial provides Canadians with immediate access to psilocybin for treatment resistant depression.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022

Retrieved on:

Thursday, May 19, 2022

Braxia's trials include Canada's first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and is expected to report preliminary results in the coming weeks.

Key Points:

Braxia's trials include Canada's first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and is expected to report preliminary results in the coming weeks.
Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others.
Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform.
These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.